对于efgartigimod alfa的营销后安全问题:基于食品和药物管理局不良事件报告系统数据库的药监测分析
Jinlong Huang1,2, Hanyun Ye1, Jingyang Lin3
1Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, People's Republic of China.
使用FDA数据分析了efgartigimod alfa (EA) 的现实世界不良事件 (AE). 该研究确定了57个AE信号,随着时间的推移,风险会减少,为EA提供了洞察力.
科学领域:
- 药物监督 药物监督 药物监督
- 药品安全 药品安全
- 免疫学 免疫学 免疫学
背景情况:
- 阿尔法 (EA) 是FDA批准的一种药物,向新生儿的Fc受体.
- 需要进一步调查EA的现实世界不良事件 (AE) 概况.
研究的目的:
- 分析efgartigimod alfa (EA) 的现实世界不良事件 (AE) 档案.
- 识别EA临床使用相关的潜在安全信号和风险.
主要方法:
- 使用了美国FDA不良事件报告系统数据库 (2021年第四季度-2024年第三季度).
- 使用不成比例分析,包括ROR,PRR,BCPNN和MGPS算法来检测AE信号.
主要成果:
- 处理了3,182个AE报告,在14个系统器官类别中识别了57个重要的AE信号.
- 关键信号包括"手术和医疗程序"和"腹膜麻".
- 观察到意想不到的副作用,如跌倒,败血症和心房动,中位数AE发作时间为101.5天.
结论:
- 突出了潜在的副作用和EA临床使用相关的风险.
- 提供了关于efgartigimod alfa.临床安全概况的重要证据.
更多相关视频
08:56Detection of Regulated Ergot Alkaloids in Food Matrices by Liquid Chromatography-Trapped Ion Mobility Spectrometry-Time-of-Flight Mass Spectrometry
Published on: November 22, 2024
05:45Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
Published on: October 10, 2025
相关概念视频
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Drug Regulation
FDA Approved Drugs: Changes to Approved Drugs
Therapeutic Drug Monitoring: Affecting Factors
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
